Cover Image
市場調查報告書

ContraFect Corporation的產品平台分析

ContraFect Corporation - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253751
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
ContraFect Corporation的產品平台分析 ContraFect Corporation - Product Pipeline Review - 2016
出版日期: 2016年07月13日 內容資訊: 英文 39 Pages
簡介

ContraFect Corporation是美國生物科技企業,正在開發消滅惡性及抗藥性之微生物的技術及治療藥、產品,治療藥有針對抗藥性葡萄菌和流感,克陽性菌引發的感染症之藥劑。

本報告提供ContraFect Corporation的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

ContraFect Corporation的基本資料

  • ContraFect Corporation概要
  • 主要資訊
  • 企業資料

ContraFect Corporation:R&D概要

  • 主要的治療範圍

ContraFect Corporation:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

ContraFect Corporation:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

ContraFect Corporation:藥物簡介

  • CF-301
  • CF-401
  • CF-402
  • CF-403
  • CF-404
  • Monoclonal Antibody 1 for Influenza
  • CF-302
  • CF-303
  • CF-304
  • CF-305
  • CF-306
  • CF-307
  • CF-308
  • CF-309
  • Monoclonal Antibodies for Influenza

ContraFect Corporation:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

ContraFect Corporation:最新的開發平台資訊

ContraFect Corporation:開發暫停中的計劃

ContraFect Corporation:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08083CDB

Summary

Global Markets Direct's, 'ContraFect Corporation - Product Pipeline Review - 2016', provides an overview of the ContraFect Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ContraFect Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of ContraFect Corporation
  • The report provides overview of ContraFect Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses ContraFect Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features ContraFect Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate ContraFect Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for ContraFect Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding ContraFect Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ContraFect Corporation Snapshot
    • ContraFect Corporation Overview
    • Key Information
    • Key Facts
  • ContraFect Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • ContraFect Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ContraFect Corporation - Pipeline Products Glance
    • ContraFect Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • ContraFect Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ContraFect Corporation - Drug Profiles
    • CF-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-402
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-403
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-404
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 for Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-302
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-303
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-304
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-305
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-306
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-307
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-308
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-309
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ContraFect Corporation - Pipeline Analysis
    • ContraFect Corporation - Pipeline Products by Target
    • ContraFect Corporation - Pipeline Products by Route of Administration
    • ContraFect Corporation - Pipeline Products by Molecule Type
    • ContraFect Corporation - Pipeline Products by Mechanism of Action
  • ContraFect Corporation - Recent Pipeline Updates
  • ContraFect Corporation - Dormant Projects
  • ContraFect Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ContraFect Corporation, Key Information
  • ContraFect Corporation, Key Facts
  • ContraFect Corporation - Pipeline by Indication, 2016
  • ContraFect Corporation - Pipeline by Stage of Development, 2016
  • ContraFect Corporation - Monotherapy Products in Pipeline, 2016
  • ContraFect Corporation - Phase I, 2016
  • ContraFect Corporation - Preclinical, 2016
  • ContraFect Corporation - Discovery, 2016
  • ContraFect Corporation - Pipeline by Target, 2016
  • ContraFect Corporation - Pipeline by Route of Administration, 2016
  • ContraFect Corporation - Pipeline by Molecule Type, 2016
  • ContraFect Corporation - Pipeline Products by Mechanism of Action, 2016
  • ContraFect Corporation - Recent Pipeline Updates, 2016
  • ContraFect Corporation - Dormant Developmental Projects,2016

List of Figures

  • ContraFect Corporation - Pipeline by Top 10 Indication, 2016
  • ContraFect Corporation - Pipeline by Stage of Development, 2016
  • ContraFect Corporation - Monotherapy Products in Pipeline, 2016
  • ContraFect Corporation - Pipeline by Target, 2016
  • ContraFect Corporation - Pipeline by Molecule Type, 2016
  • ContraFect Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top